Key Stats for UnitedHealth Stock
- Current Price: $399.36
- Target Price (Mid): ~$645
- Street Target: ~$389
- Potential Total Return: ~63%
- Annualized IRR: ~11% / year
- Earnings Reaction: +7.93% (April 21, 2026)
- Max Drawdown: -37.22% (August 1, 2025)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
UnitedHealth Group (UNH) closed at $399.36 on May 13, 2026, up roughly 47% from $270.59 at the end of March. For a company that lost over $200 billion in market value across 16 months of compounding crises, including a federal criminal investigation, the fatal shooting of UnitedHealthcare CEO Brian Thompson, two earnings disappointments, and a Medicare reimbursement squeeze, the pace of recovery is striking.
The tension now is whether this is a genuine fundamental reset or a relief rally built on a single good quarter. Bulls point to Q1 adjusted EPS of $7.23, a medical benefit ratio ahead of analyst expectations, and three significant catalysts since April. Goldman Sachs added UNH to its U.S. Conviction Buy list on May 1, citing a bottoming Medicare Advantage underwriting cycle. Evercore ISI raised its price target to $400 with an Outperform rating after the Q1 beat. And on May 5, UnitedHealth announced it would eliminate prior authorization requirements for 30% of its medical services by year-end, responding directly to regulatory pressure and public backlash around care access.
Bears point to a DOJ criminal and civil investigation with no resolution timeline, membership contracting by 1.3 million in 2026, and a stock now trading at nearly 21x forward earnings.
The Number That Actually Mattered in Q1
The most important figure in the Q1 report was the medical care ratio (MCR), which measures the share of premium revenue UnitedHealth pays out in medical claims. Lower is better. At 83.9%, it improved from 84.8% a year earlier after being under severe pressure throughout 2025.
CFO Wayne DeVeydt attributed the improvement on the call to “pricing discipline, strong medical cost management, and favorable reserve development.” He flagged a seasonal tailwind from lower respiratory activity, and was clear that this will not fully repeat in Q2, partly because of Medicare Part D seasonality changes that front-load earnings into the first half of the year.
The more durable signal is the pricing discipline behind the number. UnitedHealthcare CEO Tim Noel confirmed on the call that Q1 trends were tracking the elevated pricing assumptions the company built into 2026 plans, with “modest favorability in government programs.” The company deliberately traded membership for margin in 2026, cutting roughly 1.3 million Medicare Advantage lives to exit underpriced plans. Painful in the short term, intentional for the long term.
Operating cash flow of $8.9 billion in Q1, or 1.4x net income per DeVeydt’s remarks, confirms the earnings quality is not purely accounting-driven. UnitedHealth brought its debt-to-capital ratio to 42.9%, on track for its year-end goal of 40%, and accelerated share repurchases ahead of plan, targeting at least $2 billion deployed by the end of Q2.
See historical and forward estimates for UnitedHealth stock (It’s free!) >>>
Optum Health: The Segment That Broke the Company Is Rebuilding
Optum Health’s Q1 2026 adjusted earnings of $1.3 billion are the most concrete sign of recovery in the segment that caused the most damage in 2025. In 2024, Optum Health generated $7.77 billion in operating income. In 2025, it swung to a $278 million operating loss, the biggest drag on the company’s collapse.
On the Q1 call, Krista Nelson of Optum Health described two drivers. First, favorable prior-period reserve development concentrated in markets where clinical management had already improved. Second, a 12% year-over-year increase in patient-facing hours, driven by standardized scheduling now in place across nearly 70% of care settings.
The West region results make the mechanics clear. In response to rising patient acuity (sicker, higher-cost patients), the company deployed more data-driven care coordination around hospital admissions and skilled nursing facility transitions. Clinical reviews increased more than 50% in a single quarter, and skilled nursing admissions fell approximately 35% in the first month against prior-year levels.
This is the premise of value-based care, where providers are paid based on patient health outcomes rather than the volume of services. The company is now scaling these improvements to other markets, and management signaled a clear path toward Optum Health’s long-term operating margin target of 6% to 8% by 2027.
On May 13, Optum Rx disclosed a new transparent, fee-based pricing model, responding directly to PBM (pharmacy benefit manager) reform legislation and positioning the segment ahead of peers on transparency.
The AI Bet: $1.5 Billion With a 2:1 Return Target
UnitedHealth is investing nearly $1.5 billion in AI in 2026, split roughly one-third into Optum Insight’s AI-first software products and two-thirds into enterprise-wide process transformation across claims, prior authorization, and clinical workflows.
Sandeep Dadlani, who oversees digital and technology strategy at UnitedHealth Group, laid out the return target on the call: a conservative 2:1 return on these programs over the next few years, with many paying back within 12 to 18 months. The generative AI chatbot Avery will reach over 20 million UnitedHealthcare members by year-end. The Optum Real platform, an AI-first claims processing tool, processed 0.5 billion transactions year-to-date in Q1 and is tracking toward over 2.5 billion by year-end.
On the pharmacy side, Optum Rx’s PreCheck Prior Authorization tool reduces prescription approval time from over 8 hours to under 30 seconds, with a 68% reduction in denials from missing information and an 88% reduction in appeals. On the medical side, the May 5 prior authorization announcement is a separate initiative covering medical services broadly, not just pharmacy.
CEO Stephen Hemsley framed the ambition directly on the call: “This is not just a matter of being more productive at what we already do, but a reimagining of how we organize, operate, and work going forward.” Optum Insight’s AI-related revenue benefits are expected to be back-half weighted in 2026 and more visible in 2027, as legacy non-AI products are decommissioned.
For investors tracking earnings surprises and revisions across the Optum segments, 2027 is when management expects the AI investments to show up clearly in the financials.
The Risk That Doesn’t Go Away
The DOJ investigation remains the central reason the bear case is not easily dismissed. The Department of Justice is conducting criminal and civil investigations into UnitedHealth’s Medicare Advantage billing practices, specifically whether the company inflated patient diagnoses to trigger higher government reimbursements. No resolution timeline has been announced.
The structural Medicare Advantage funding pressure also persists. Even with CMS’s finalized 2.48% average rate increase for 2027 Medicare Advantage plans, far better than the near-flat proposal that triggered UNH’s worst single-session drop in January 2026, UnitedHealthcare’s Bobby Hunter told analysts on the Q1 call that “widely expected medical trend for 2027 is still meaningfully above these funding levels.” The company is targeting the upper half of its 2% to 4% long-term Medicare Advantage margin range by 2027, but it is not there yet.
From a balance sheet standpoint, UNH carries $49.9 billion in net debt against $21.5 billion in LTM EBITDA, a 2.16x leverage ratio that is manageable given the cash generation. LTM free cash flow of approximately $17.7 billion remains solid. On valuation, UNH trades at 14.27x NTM EV/EBITDA and 20.95x NTM P/E, expanded from 2025 troughs but below pre-crisis levels.
See how UnitedHealth performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $399.36
- Target Price (Mid): ~$645
- Potential Total Return: ~63%
- Annualized IRR: ~11% / year
See analysts’ growth forecasts and price targets for UnitedHealth stock (It’s free!) >>>
The TIKR mid-case uses a revenue CAGR of around 6% through 12/31/30, well below UNH’s 10-year historical rate of 11%, and a net income margin of around 5%, below the 6% to 6.4% the company averaged from 2021 to 2024. These are conservative assumptions that do not require UNH to return to peak performance.
The two primary revenue CAGR drivers are Medicare Advantage repricing flowing through 2027 and 2028 as the 2026 membership contraction stabilizes, and Optum Rx growth through new client onboarding and its transparent fee-based model. The primary margin driver is Optum Health’s recovery toward its 6% to 8% long-term target, which Q1 2026 results suggest is on track.
The primary risk to the mid-case is the DOJ investigation. Forced restructuring of Optum’s physician business would directly undermine the integrated care model that every margin scenario depends on.
Conclusion
The single number to watch is the Q2 2026 medical care ratio. Management guided that some favorable Q1 dynamics, including lower respiratory activity and seasonal patterns, will moderate in Q2. A second-quarter MCR holding in line with guidance confirms the pricing discipline is structural. A meaningful deterioration raises the question of whether Q1 was a turning point or an outlier.
Q2 earnings are expected in late July 2026. At $399, UNH is no longer the distressed asset it was in March. The TIKR mid-case offers roughly 63% upside through 2030, built on conservative assumptions that a successful turnaround would likely exceed. The DOJ investigation is the variable no model can price, and the one thing that could break the thesis entirely if it goes the wrong way.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in UnitedHealth?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up UnitedHealth, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track UnitedHealth alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze UnitedHealth on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
